Citation Impact
Citing Papers
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
2009 Standout
Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients
2011
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
2007 Standout
Immunomodulatory Function of Interleukin 28B During Primary Infection With Cytomegalovirus
2014 StandoutNobel
Foscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study
1998
High Risk of Death Due to Bacterial and Fungal Infection among Cytomegalovirus (CMV)–Seronegative Recipients of Stem Cell Transplants from Seropositive Donors: Evidence for Indirect Effects of Primary CMV Infection
2002
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2014 Standout
Endoscopic and histologic diagnosis of intestinal graft-versus-host disease after marrow transplantation
1999
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
2009 Standout
Prognostic relevance of ‘early‐onset’ graft‐versus‐host disease following non‐myeloablative haematopoietic cell transplantation
2005
Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease
2007 Standout
European evidence based consensus for endoscopy in inflammatory bowel disease
2013 Standout
INFECTIONS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION
2001
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Prophylaxis Followed by Preemptive Therapy Versus Preemptive Therapy for Prevention of Human Cytomegalovirus Disease in Pediatric Patients Undergoing Liver Transplantation
2008
Tuberculosis after hematopoietic stem cell transplantation: incidence, clinical characteristics and outcome
2000
Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation
2006
Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments
2004
Utility of Leflunomide in the Treatment of Complex Cytomegalovirus Syndromes
2010
Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation
2003
Chronic graft-versus-host disease
2003 Standout
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
2011 Standout
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017 Standout
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Transferred Herpes Simplex Virus Immunity after Stem‐Cell Transplantation: Clinical Implications
2003
Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath ‘in the bag’ as T-cell depletion: the Leiden experience
2006
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017 Standout
Levels of CMV Specific CD4 T Cells Are Dynamic and Correlate with CMV Viremia after Allogeneic Stem Cell Transplantation
2008
Ganciclovir
2001
Graft-versus-host disease
2009 Standout
Late Cytomegalovirus Disease in Marrow Transplantation Is Predicted by Virus Load in Plasma
1997
Echinocandin antifungal drugs
2003 Standout
Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients
2001
Specific endoscopic features of ulcerative colitis complicated by cytomegalovirus infection
2010
Risk Factors, Clinical Characteristics, and Outcome of Nocardia Infection in Organ Transplant Recipients: A Matched Case-Control Study
2007 Standout
Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation
2010 Standout
Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial
2011
Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?
2007 Standout
The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation
2018 Standout
Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: A matched control study
2002
SUCCESSFUL PREEMPTIVE CIDOFOVIR TREATMENT FOR CMV ANTIGENEMIA AFTER DOSE-REDUCED CONDITIONING AND ALLOGENEIC BLOOD STEM CELL TRANSPLANTATION
2001
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Defining the Intensity of Conditioning Regimens: Working Definitions
2009 Standout
Candidemia in Allogeneic Blood and Marrow Transplant Recipients: Evolution of Risk Factors after the Adoption of Prophylactic Fluconazole
2000
Preemptive therapy for cytomegalovirus based on real-time measurement of viral load in liver transplant recipients
2010
Review and meta‐analysis of the epidemiology of congenital cytomegalovirus (CMV) infection
2007 Standout
Immunity to fungal infections
2011 Standout
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
2010 Standout
Cytomegalovirus disease before hematopoietic cell transplantation as a risk for complications after transplantation
2005
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Cytomegalovirus Infections following Umbilical Cord Blood Transplantation Using Reduced Intensity Conditioning Regimens for Adult Patients
2007
Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias
2002
Serum bilirubin levels and mortality after myeloablative allogeneic hematopoietic cell transplantation†
2005
Epidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients
2002 Standout
Clinical Protocol: A Phase I-II Trial to Examine the Toxicity of CMV- and EBV-Specific Cytotoxic T Lymphocytes When Used for Prophylaxis against EBV and CMV Disease in Recipients of CD34-Selected/T Cell-Depleted Stem Cell Transplants
2000
Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors
2002
Multicenter quality control study for human cytomegalovirus DNAemia quantification.
2009
Diagnosis and Management of Human Cytomegalovirus Infection in the Mother, Fetus, and Newborn Infant
2002
Acute Myeloid Leukemia
2015 Standout
Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities
2004
Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation
2003
Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision
2017 Standout
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants
2002
Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial
2003
Corticosteroids can reverse severe imatinib-induced hepatotoxicity.
2006
Extended routine polymerase chain reaction surveillance and pre‐emptive antiviral therapy for cytomegalovirus after allogeneic transplantation
2000
Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation
2003
2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer
2002 Standout
Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study
2002
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
Prophylaxis against fungal infections and cytomegalovirus disease after bone marrow transplantation.
2000
Infusion of cytomegalovirus (CMV)–specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy
2002
Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of preemptively treated children and young adults receiving hematopoietic stem-cell transplantation compared with qualitative pp65 antigenemia
2007
Multicenter evaluation of efficacy and safety of low‐dose versus high‐dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients
2016
Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation
2000
Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation
2001
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
2005 Standout
Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America
2008 Standout
Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial
2000
Quantitation of Cytomegalovirus: Methodologic Aspects and Clinical Applications
1998
Guidelines for Preventing Health-Care-Associated Pneumonia, 2003: Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee
2004 Standout
Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes
2001
Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia
2007
Successful Modification of a pp65 Antigenemia-Based Early Treatment Strategy for Prevention of Cytomegalovirus Disease in Allogeneic Marrow Transplant Recipients
1999
2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
2013 Standout
Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization
2020 StandoutNobel
Guidelines for Treatment of Candidiasis
2004 Standout
Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients
2001
Successful Modification of a pp65 Antigenemia-Based Early Treatment Strategy for Prevention of Cytomegalovirus Disease in Allogeneic Marrow Transplant Recipients
1999
Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders
2002
Increased Incidence of Cytomegalovirus Disease After Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation
1999
Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning
2003
Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation
2001
Works of T Cunningham being referenced
Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study
1996